Document is current

Article History

Received: 12 June 2018

Accepted: 9 January 2019

First Online: 28 January 2019

Ethics approval and consent to participate

: All subjects provided written informed consent. The OLiVIA study was approved by the ethics committee of the University Medical Center Groningen on March 19th, 2013 and is known under reference number M13.133950.

: Not applicable.

: CC, IB, SV, SS, AL, JV, MF and NtH have nothing to disclose. HF reports other from MEDA, other from AstraZeneca, outside the submitted work. PH has a patent on the Novolizer with royalties paid, a patent on the Genuair with royalties paid, and a patent on the Twincer with royalties paid. HK reports that his institution has received grants from TEVA in relation to the submitted work, as well as consultancy fees from Novartis, GlaxoSmithKline, Fluidda, AstraZeneca, and Boehringer Ingelheim outside the submitted work. MvdB reports grants paid to the University from Astra Zeneca, TEVA, GSK, Chiesi, outside the submitted work.The current work was sponsored by supported by TEVA pharmaceutical Industries Ltd., which was in no way involved in study design, writing or reviewing of the manuscript.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.